MX2021016117A - Complejos peptidos-mhc. - Google Patents

Complejos peptidos-mhc.

Info

Publication number
MX2021016117A
MX2021016117A MX2021016117A MX2021016117A MX2021016117A MX 2021016117 A MX2021016117 A MX 2021016117A MX 2021016117 A MX2021016117 A MX 2021016117A MX 2021016117 A MX2021016117 A MX 2021016117A MX 2021016117 A MX2021016117 A MX 2021016117A
Authority
MX
Mexico
Prior art keywords
peptide
complex
mhc complexes
mhc
pmhc
Prior art date
Application number
MX2021016117A
Other languages
English (en)
Inventor
Thomas Holberg Blicher
Souza Victoria Arena De
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of MX2021016117A publication Critical patent/MX2021016117A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona un complejo de péptido-MHC (pMHC) estabilizado, tal como un complejo péptido-HLA-E. El complejo tiene un enlace no nativo, tal como un enlace disulfuro, entre el residuo de anclaje C terminal del péptido y un residuo de aminoácido en la cavidad F de la ranura de unión del MHC.
MX2021016117A 2019-07-02 2020-07-01 Complejos peptidos-mhc. MX2021016117A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1909509.0A GB201909509D0 (en) 2019-07-02 2019-07-02 Peptide-MHC complexes
PCT/EP2020/068491 WO2021001414A1 (en) 2019-07-02 2020-07-01 Peptide-mhc complexes

Publications (1)

Publication Number Publication Date
MX2021016117A true MX2021016117A (es) 2022-06-08

Family

ID=67540088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016117A MX2021016117A (es) 2019-07-02 2020-07-01 Complejos peptidos-mhc.

Country Status (12)

Country Link
US (1) US20230054274A1 (es)
EP (1) EP3994161A1 (es)
JP (1) JP2022538922A (es)
KR (1) KR20220031046A (es)
CN (1) CN114174329A (es)
AU (1) AU2020299989A1 (es)
BR (1) BR112021026149A2 (es)
CA (1) CA3143567A1 (es)
GB (1) GB201909509D0 (es)
IL (1) IL289390A (es)
MX (1) MX2021016117A (es)
WO (1) WO2021001414A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202010329D0 (en) * 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
EP4271704A1 (en) * 2020-12-31 2023-11-08 Oxford University Innovation Limited Mhc: peptide complexes
WO2022254200A1 (en) * 2021-06-01 2022-12-08 Oxford University Innovation Limited Peptide screen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69730038T2 (de) * 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
CA2440773A1 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
GB0411773D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
ATE555383T1 (de) * 2006-06-22 2012-05-15 Novo Nordisk As Lösliche heterodimere rezeptoren und ihre verwendung
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
US9494588B2 (en) 2011-08-30 2016-11-15 Jacobs University Bremen Ggmbh Gene coded for a MHC class I molecule, plasmid, expression system protein, multimer, reagent and kit to analyze a T cell frequency
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
CA3025894A1 (en) * 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein

Also Published As

Publication number Publication date
CN114174329A (zh) 2022-03-11
GB201909509D0 (en) 2019-08-14
IL289390A (en) 2022-02-01
WO2021001414A1 (en) 2021-01-07
AU2020299989A1 (en) 2022-02-17
BR112021026149A2 (pt) 2022-02-08
CA3143567A1 (en) 2021-01-07
EP3994161A1 (en) 2022-05-11
JP2022538922A (ja) 2022-09-06
US20230054274A1 (en) 2023-02-23
KR20220031046A (ko) 2022-03-11

Similar Documents

Publication Publication Date Title
MX2021016117A (es) Complejos peptidos-mhc.
MX2023001403A (es) Neoantigenos y metodos de su uso.
MX2012002357A (es) Composiciones que inducen la ayuda de las celulas t.
MX2019005272A (es) Peptidos cancerigenos universales derivados de telomerasa.
WO2018187356A3 (en) Protein antigens and uses thereof
CL2021001776A1 (es) Péptidos y combinación de péptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres (divisional de la solicitud no. 201702448)
MY200973A (en) Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
BR112018070625A2 (pt) receptores de células t
WO2017075522A3 (en) Glp-2 polypeptides with improved proteolytic stability, and methods of preparing and using same
MX2020005561A (es) Proteinas modificadas de union a adn.
WO2018050902A3 (en) Multimers, tetramers & octamers
SA519401646B1 (ar) الجلوبولينات المناعية واستخداماتها
WO2009007714A3 (en) Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
MX2020012124A (es) Polipeptidos de unión bifuncional.
NZ756224A (en) Polypeptide variants and uses thereof
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
WO2018213585A8 (en) Conjugation of peptides to spherical nucleic acids (snas) using traceless linkers
MX2021011535A (es) Agente de edición activa de genes dirigida y métodos de uso.
ZA202106602B (en) Claudin 6 antibodies and uses thereof
NZ765759A (en) Atf5 peptide variants and uses thereof
PH12016500371B1 (en) Stable polypeptides binding to human complement c5
MX2021011536A (es) Agente de edición dirigida de genes activos y métodos de uso.
NZ589365A (en) Peptidyl diacylglycerides
CR20220065A (es) Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc
NZ744289A (en) Composition containing amino acids